Drug Type TCR therapy |
Synonyms GB3007 NY-ESO1 TCRT |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | CN | - | |
Synovial Sarcoma | Discovery | CN | 30 Jan 2022 |